S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, vol.360, pp.1903-1913, 2002.

P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton et al., Global burden of hypertension: analysis of worldwide data, Lancet, vol.365, pp.217-223, 2005.

S. Verlohren, D. N. Muller, F. C. Luft, and R. Dechend, Immunology in hypertension, preeclampsia, and target-organ damage, Hypertension, vol.54, pp.439-443, 2009.

M. Clozel, H. Kuhn, F. Hefti, and H. R. Baumgartner, Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition, Hypertension, vol.18, pp.132-141, 1991.

M. Franco, F. Martinez, Y. Quiroz, O. Galicia, R. Bautista et al., Renal angiotensin II concentration and interstitial infiltration of immune cells are correlated with blood pressure levels in salt-sensitive hypertension, Am J Physiol, vol.293, pp.251-256, 2007.

B. Rodriguez-iturbe, N. D. Vaziri, and R. J. Johnson, Inflammation, angiotensin II, and hypertension, Hypertension, vol.52, 2008.

A. Machnik, W. Neuhofer, J. Jantsch, A. Dahlmann, T. Tammela et al., Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism, Nat Med, vol.15, pp.545-552, 2009.

P. Wenzel, M. Knorr, S. Kossmann, J. Stratmann, M. Hausding et al., Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction, Circulation, vol.124, pp.1370-1381, 2011.

S. D. Crowley, Y. S. Song, G. Sprung, R. Griffiths, M. Sparks et al., A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension, Hypertension, vol.55, pp.99-108, 2010.

A. J. Rickard, J. Morgan, G. Tesch, J. W. Funder, P. J. Fuller et al., Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure, Hypertension, vol.54, pp.537-543, 2009.

M. Yanagisawa, H. Kurihara, S. Kimura, Y. Tomobe, M. Kobayashi et al., A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, vol.332, pp.411-415, 1988.

E. I. Boesen, J. M. Sasser, M. A. Saleh, W. A. Potter, M. Woods et al., Interleukin-1beta, but not interleukin-6, enhances renal and systemic endothelin production in vivo, Am J Physiol, vol.295, pp.446-453, 2008.

A. H. Sprague and R. A. Khalil, Inflammatory cytokines in vascular dysfunction and vascular disease, Biochem Pharmacol, vol.78, pp.539-552, 2009.

H. Arai, S. Hori, I. Aramori, H. Ohkubo, and S. Nakanishi, Cloning and expression of a cDNA encoding an endothelin receptor, Nature, vol.348, pp.730-732, 1990.

T. Sakurai, M. Yanagisawa, Y. Takuwa, H. Miyazaki, S. Kimura et al., Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor, Nature, vol.348, pp.732-735, 1990.

A. P. Davenport, G. O'reilly, P. Molenaar, J. J. Maguire, R. E. Kuc et al., Human endothelin receptors characterized using reverse transcriptasepolymerase chain reaction, in situ hybridization, and subtype-selective ligands BQ123 and BQ3020: evidence for expression of ETB receptors in human vascular smooth muscle, J Cardiovasc Pharmacol, vol.22, pp.22-25, 1993.

M. C. Verhaar, F. E. Strachan, D. E. Newby, N. L. Cruden, H. A. Koomans et al., Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade, Circulation, vol.97, pp.752-756, 1998.

D. E. Newby, F. E. Strachan, and D. J. Webb, Abnormal endothelin B receptor vasomotor responses in patients with Hirschprung's disease, QJM, vol.95, pp.159-163, 2002.

E. L. Schiffrin, Role of endothelin-1 in hypertension, Hypertension, vol.34, pp.876-881, 1999.

S. Rajagopalan, J. B. Laursen, A. Borthayre, S. Kurz, J. Keiser et al., Role for endothelin-1 in angiotensin II-mediated hypertension, Hypertension, vol.30, pp.29-34, 1997.

P. Moreau, L. V. Uscio, S. Shaw, H. Takase, M. Barton et al., Angiotensin II increases tissue endothelin and induces vascular hypertrophy. Reversal by ET Areceptor antagonist, Circulation, vol.96, pp.1593-1597, 1997.

H. Krum, R. J. Viskoper, Y. Lacourciere, M. Budde, and V. Charlon, The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension, N Engl J Med, vol.338, pp.784-790, 1998.

R. Nakov, E. Pfarr, and S. Eberle, Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension, Am J Hypertens, vol.15, pp.583-589, 2002.

M. A. Weber, H. Black, G. Bakris, H. Krum, S. Linas et al., A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial, Lancet, vol.374, pp.1423-1431, 2009.

E. I. Boesen, K. R. Krishnan, J. S. Pollock, and D. M. Pollock, ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells, J Am Soc Nephrol, vol.22, pp.2187-2192, 2011.

R. C. Tostes, R. M. Touyz, G. He, F. Ammarguellat, and E. L. Schiffrin, Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats, J Cardiovasc Pharmacol, vol.39, pp.892-900, 2002.

J. M. Sasser, J. C. Sullivan, J. L. Hobbs, T. Yamamoto, D. M. Pollock et al., Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism, J Am Soc Nephrol, vol.18, pp.143-154, 2007.

M. Santosuosso, M. Divangahi, A. Zganiacz, and Z. Xing, Reduced tissue macrophage population in the lung by anticancer agent cyclophosphamide: restoration by local granulocyte macrophage-colony-stimulating factor gene transfer, Blood, vol.99, pp.1246-1252, 2002.

T. Barhoumi, D. A. Kasal, M. W. Li, L. Shbat, P. Laurant et al., T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury, Hypertension, vol.57, pp.469-476, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01333877

J. D. Zhang, M. B. Patel, Y. S. Song, R. Griffiths, J. Burchette et al., A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension, Circ Res, vol.110, pp.1604-1617, 2012.

T. J. Guzik, N. E. Hoch, K. A. Brown, L. A. Mccann, A. Rahman et al., Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction, J Exp Med, vol.204, pp.2449-2460, 2007.

D. Javeshghani, T. Barhoumi, N. Idris-khodja, P. Paradis, and E. L. Schiffrin, Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury, Hypertension, vol.62, pp.112-117, 2013.

A. Chow, B. D. Brown, and M. Merad, Studying the mononuclear phagocyte system in the molecular age, Nat Rev Immunol, vol.11, pp.788-798, 2011.

J. S. Duffield, S. J. Forbes, C. M. Constandinou, S. Clay, M. Partolina et al., Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair, J Clin Invest, vol.115, pp.56-65, 2005.

D. A. Ferenbach, T. A. Sheldrake, K. Dhaliwal, T. M. Kipari, L. P. Marson et al., Macrophage/monocyte depletion by clodronate, but not diphtheria toxin, improves renal ischemia/reperfusion injury in mice, Kidney Int, vol.82, pp.928-933, 2012.

B. E. Clausen, C. Burkhardt, W. Reith, R. Renkawitz, and I. Forster, Conditional gene targeting in macrophages and granulocytes using LysMcre mice, Transgen Res, vol.8, pp.265-277, 1999.

R. Spirig, I. Potapova, J. Shaw-boden, J. Tsui, R. Rieben et al., TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells, Mol Immunol, vol.46, pp.3178-3182, 2009.

G. Slobodin, E. Pavlotzky, J. Panov, I. Rosner, A. Kessel et al., Endothelin-1 does not change the function of monocyte-derived dendritic cells grown from patients with systemic sclerosis, Immunol Invest, vol.37, pp.841-848, 2008.

. .. ,

W. C. Sessa, S. Kaw, A. Zembowicz, E. Anggard, M. Hecker et al., Human polymorphonuclear leukocytes generate and degrade endothelin-1 by two distinct neutral proteases, J Cardiovasc Pharmacol, vol.17, pp.34-38, 1991.

A. A. Elmarakby, E. D. Loomis, J. S. Pollock, and D. M. Pollock, NADPH oxidase inhibition attenuates oxidative stress but not hypertension produced by chronic ET-1, Hypertension, vol.45, pp.283-287, 2005.

M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, and D. M. Pollock, Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat, Hypertension, vol.56, pp.942-949, 2010.

A. J. Bagnall, N. F. Kelland, F. Gulliver-sloan, A. P. Davenport, G. A. Gray et al., Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt, Hypertension, vol.48, pp.286-293, 2006.

H. Ruetten and C. Thiemermann, Endothelin-1 stimulates the biosynthesis of tumour necrosis factor in macrophages: ET-receptors, signal transduction and inhibition by dexamethasone, J Physiol Pharmacol, vol.48, pp.675-688, 1997.

S. H. Wilson, R. D. Simari, and A. Lerman, The effect of endothelin-1 on nuclear factor kappa B in macrophages, Biochem Biophys Res Commun, vol.286, pp.968-972, 2001.

H. Ehrenreich, R. W. Anderson, C. H. Fox, P. Rieckmann, G. S. Hoffman et al., Endothelins, peptides with potent vasoactive properties, are produced by human macrophages, J Exp Med, vol.172, pp.1741-1748, 1990.

N. Said, S. Smith, M. Sanchez-carbayo, and D. Theodorescu, Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer, J Clin Invest, vol.121, pp.132-147, 2011.

C. C. Chen, L. L. Chen, Y. T. Hsu, K. J. Liu, C. S. Fan et al., The endothelin-integrin axis is involved in macrophage-induced breast cancer cell chemotactic interactions with endothelial cells, J Biol Chem, vol.289, pp.10029-10044, 2014.

P. Oh, T. Horner, H. Witkiewicz, and J. E. Schnitzer, Endothelin induces rapid, dynaminmediated budding of endothelial caveolae rich in ET-B, J Biol Chem, vol.287, pp.17353-17362, 2012.

A. Schreiter, C. Gore, D. Labuz, M. C. Fournie-zaluski, B. P. Roques et al., Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue, FASEB J, vol.26, pp.5161-5171, 2012.

J. T. Ransom, Mechanism of action of mycophenolate mofetil, Ther Drug Monitor, vol.17, pp.681-684, 1995.

L. C. Barr, M. Brittan, A. C. Morris, D. F. Mcauley, C. Mccormack et al., A randomized controlled trial of peripheral blood mononuclear cell depletion in experimental human lung inflammation, Am J Resp Crit Care Med, vol.188, pp.449-455, 2013.

N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin et al., Role of endothelin-1 in clinical hypertension: 20 years on, Hypertension, vol.52, pp.452-459, 2008.

N. Dhaun, J. Goddard, and D. J. Webb, The endothelin system and its antagonism in chronic kidney disease, J Am Soc Nephrol, vol.17, pp.943-955, 2006.

N. Dhaun, N. R. Johnston, J. Goddard, and D. J. Webb, Chronic selective endothelin a receptor antagonism reduces serum uric Acid in hypertensive chronic kidney disease, Hypertension, vol.58, pp.11-12, 2011.

N. Dhaun, I. M. Macintyre, D. Kerr, V. Melville, N. R. Johnston et al., Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease, Hypertension, vol.57, pp.772-779, 2011.

B. Williams, G. Mancia, W. Spiering, A. Rosei, E. Azizi et al., , 2018.

. Esc/esh, Guidelines for the management of arterial hypertension, Eur Heart J, vol.39, pp.3021-3104, 2018.

A. Czopek,